{"url_path":"/sec/klrs/8-k/2026-08-11/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/1754068/0001193125-26-343477-index.html","accession_number":"0001193125-26-343477","cik":"0001754068","ticker":"KLRS","issuer_name":"Kalaris Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1754068/0001193125-26-343477-index.html","primary_entity_key":"0001754068","primary_entity_name":"Kalaris Therapeutics, Inc."},"word_count":84,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits.\n\n(d) Exhibits\n\n \n\nExhibit\n\nNo.\n\n  \nDescription\n\n99.1\n  \n[Press Release issued by Kalaris Therapeutics, Inc. on August 11, 2026](d114296dex991.htm)\n\n104\n  \nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \nKALARIS THERAPEUTICS, INC.\n\nDate: August 11, 2026\n \n\n \nBy:\n \n\n/s/ Andrew Oxtoby\n\n \n\n \nName:\n \nAndrew Oxtoby\n\n \n\n \nTitle:\n \nChief Executive Officer"}